**Explanation of Conflict of Interest Disclosure Parts:**

**Part One:** All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present)

**Part Two:** Income Sources & Equity of $10,000 or greater

**Part Three:** Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present):

**Part Four:** Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present)

**Part Five:** My primary employer is a pharmaceutical/biotech/medical device company.

**ACNP 2013 Council Disclosures**

**John Csernansky:** **Part 1:** Eli Lilly & Company, Sanofi-Aventis

**Ronald Duman:** **Part 1:** Bristol Myers Squibb, Eli Lilly & Company, Forest, Johnson & Johnson, Lundbeck, Pfizer; **Part 4:** Eli Lilly & Company, Lundbeck, Johnson & Johnson, Forest

**Alan Frazer:** Part 1: Lundbeck, Cyberonics, Takeda, Eli Lilly & Company; **Part 4:** Lundbeck

**Suzanne Haber:** **Part 1:** Medtronic, Inc., Pfizer

**John Krystal:** **Part 1:** AbbVie, Inc., AMGEN, AstraZeneca, Biological Psychiatry, Bristol-Myers Squibb, Eli Lilly and Co. Otsuka Pharmaceutical Development & Commercialization, Quintiles Consulting, Sage Therapeutics, Inc., Shire Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Takeda Industries, Teva Pharmaceutical Industries, Ltd.; **Part 2:** Biological Psychiatry Editor; **Part 4:** Janssen Research Foundation Patents and Inventions


2) Vladimir, Coric, Krystal, John Hm, Sanacora, Gerard – Glutamate Agents in the Treatment of Mental Disorders No. 11/399,188 April 5, 2006 (Pending)

3) Intranasal Administration of Ketamine to Treat Depression (pending)

**David Kupfer:** **Part 1:** Sevier (spouse), Guilford Press (spouse); **Part 2:** American Psychiatric Association, Sevier (spouse)

**David Lewis:** **Part 1:** Bristol-Myers Squibb, Concert; **Part 4:** Bristol-Myers Squibb Foundation, Bristol-Myers Squibb, Curridium Ltd, Pfizer

**Robert Malenka:** **Part 1:** Circuit Therapeutics, Inc.; **Part 2:** Circuit Therapeutics, Inc.

**Eric Nestler:** **Part 1:** PsychoGenics, Berg Pharma, Merck Research Laboratories, Johnson & Johnson; **Part 2:** PsychoGenics, Berg Pharma, Merck Research Laboratories; **Part 3:** Berg Pharma, Merck Research Laboratories; **Part 4:** Johnson & Johnson
Council Members with No Disclosures
Karen Berman
Linda Brady
Barry Everitt, Council-Elect
Peter Kalivas
Marina Wolf, Council-Elect
Ronnie Wilkins, Executive Director

2013 Program Committee Disclosures

Anissa Abi-Dargham: Part 1: Otsuka, Shire, Roche, BMS, Pfizer, Takeda, Amgen, Forest, Pierre Fabre, Part 4: Pierre Fabre, Forest

Randy Blakely: Part 1: Lundbeck Amgen, Part 4: Amgen

Ariel Deutch: Part 1: Eli Lilly

Paul Kenny: Part 1: Eolas Therapeutics


Pat Levitt: Part 1: Scientific Advisory Board for Pediatric Biosciences

Stephen Marder: Part 1: Abbott, Roche, Genentech, Otsuka, Shire, EnVivo, Targacept, Pfizer, Lundbeck, Bristol Meyers Squibb, Part 4: Sunovion, Novartis, Amgen, Psychogenics


Daniel Mathalon: Part 1: I am a consultant for Bristol-Myers Squibb I am a consultant for Amgen, Part 4: 2011-AstraZeneca investigator initiated grant

Colleen McClung: Part 1: I received honorarium for a seminar given at Johnson & Johnson in 2012, Part 4: I received a grant from IMHRO partnered with Johnson & Johnson in 2012 (Rising Star Translational Research Award).

Kalpana Merchant: Part 5: Eli Lilly and Company

Lisa Monteggia: Part 1: Speaker's bureau, Roche.

Akira Sawa: Part 4: Astellas Pharm., Dainippon Sumitomo, Mitsubishi-Tanabe Pharm., Takeda, Johnson and Johnson, Asubio,Sucampo, Eli Lilly, Taisho, Pfizer, Afraxis, Sanofis-Aventis


Thomas Schulze: Part 1: Almirall (Neurofarmagen/genetic testing)

Pamela Sklar: Part 4: Sage BioNetworks

Matthew State: Part 1: Pfizer pharmaceuticals SynapDx, Part 2: Pfizer pharmaceuticals


Audrey Tyrka: Part 1: Medtronic, Neuronetics, NeoSync, Part 4: Medtronic, Neuronetics, NeoSync


Carlos Zarate: Part 1: co-inventor - patent application for the use of ketamine and its metabolites in major depression. Patent rights assigned to U.S. government; will receive a percentage of any royalties received by the government.

NOTHING TO DISCLOSE

Ted Abel
Gary Aston-Jones
Hilary Blumberg
John Bruno
Kristin Cadenhead
Joe Callicott
Stephen Deutsch
Rita Goldstein
ACNP 2013 Presenter Disclosures

Abel, Ted: Part 2: Editor, Neurobiology of Learning and Memory, Elsevier

Abi-Dargham, Anissa: Part 1: Pierre Fabre, Pfizer, Takeda, Otsuka, Amgen, Roche, Part 4: Pierre Fabre

Alexopoulos, George: Part 1: I have a research grant from Forest; have consulted for Hoffman-LaRoche, Janssen, Lilly, Navidea, Pfizer, and Otsuka; and have been on speakers’ bureaus for Astra Zeneca, Avanir, Merck, Novartis, and Sunovion., Part 2: Astra Zeneca, Forest, Merck, Sunovion, Part 4: I have received grant support from Forest


Appelbaum, Paul: Part 1: Equity interest in COVR, Inc. (violence prediction software)., Part 2: Professor, Columbia University, Research Scientist, NY State Psychiatric Institute, Private practice of general and forensic psychiatry

Arnsten, Amy: Part 1: I have recently had conversations with Pfizer, Merck, Shire and Evotec, and received a small grant from Pfizer to perform physiological assessments of one of their compounds in primate prefrontal cortex. Part 2: Yale University and I receive royalties from the sales of Intuniv from Shire Pharmaceuticals.

Banks, Matthew: Part 1: Collaborator on a grant from Perdue Pharmaceuticals related to opioid pharmacology in nonhuman primates., Part 4: Collaborator on a grant from Perdue Pharmaceuticals related to opioid pharmacology in nonhuman primates.

Baram, Tallie Z.: Part 1: Baram’s institution (UCI) received travel & consultanship; Questcor, Part 2: stock ownership, TEVA

Becker, Howard: Part 1: Dr. Becker has conducted contractual work and served as a consultant for Eli Lilly and Company, but those activities have no relationship to work that will be presented in this symposium., Part 4: Dr. Becker engaged in a research contract with Eli Lilly and Company.

Bergen, Andrew: Part 1: Dr. Bergen has had research supported by an Agreement with Perlegen Biosciences, by an Agreement with Medco Health Solutions, and with loans of equipment and reagents from Affymetrix and from Genisphere.

Bikson, Marom: Part 1: Marom Bikson has equity in Soterix Medical Inc., Part 4: Marom Bikson recieved grant support from Soterix Medical Inc.

Blennow, Kaj: Part 1: Innogenetics, Kyowa Kirin Pharma, Roche, Pfizer, BMS.

Blier, Pierre: Part 1: I participated in advisory boards, gave presentations, and/or received research grants (without a salary portion and administered by my institution) from Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Forest, Lundbeck, Merck, Otsuka, Pfizer, Roche, Takeda, and Servier


Buchanan, Robert: Part 1: Advisory Boards: Abbott; Amgen; Janssen Pharmaceutical, Inc.; NuPathe; Pfizer; Roche; Takeda; Consultant: Abbott; Amgen; Bristol-Myers Squibb; EnVivo; Omeros; Pfizer, DSMB: Otsuka; Pfizer

Bustillo, Juan: Part 1: Speakers Bureau and advisory consulting for Otsuka America Pharmaceutical Inc


Casey, Daniel: Part 1: Consultant/advisory board: Bristol-Myers Squibb, Genentech and Merck; Speaker’s bureau: Bristol-Myers Squibb, Merck and Sunovion

Chappell, Phillip: Part 1: , Part 5: Pfizer Inc

Charney, Dennis: Part 1: Dr. Charney has been named as inventors on a pending use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression
and received approval from the Food and Drug Administration for this indication, Dr. Charney and Mount Sinai School of Medicine could benefit financially.

**Coccaro, Emil**: *Part 1*: Scientific Advisory Board for Azivan Pharmaceuticals.

**Correll, Christoph**: *Part 1*: Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Merck, Janssen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Janssen/J&J, and Otsuka. *Part 2*: Bristol-Myers Squibb, Cephalon, Merck, Otsuka, Pfizer, ProPhase, *Part 4*: BMS, Janssen/J&J, and Otsuka

**Cross, Alan**: *Part 5*: Current employee of AstraZeneca Pharmaceuticals, in Wilmington DE, the company that sponsored/funded the study reported here.

**Dalmau, Josep**: *Part 1*: JD receives royalties from Athena Diagnostics for a patent for the use of Ma2 as an autoantibody test, and licensing fees from Euroimmun for a patent for the use of NMDAR as an autoantibody test.

**Daskalakis, Zafiris**: *Part 1*: Received external funding through Neuronetics and Brainsway Inc. ZJD has also served on the advisory board for Hoffmann-La Roche Limited. This work was supported by the Ontario Mental Health Foundation (OMHF), the Canadian Institutes of Health Research (CIHR), the Brain and Behaviour Research Foundation and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. *Part 4*: Brainsway Inc.

**Davis, Kenneth**: *Part 1*: My wife, Bonnie M. Davis, MD is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license. *Part 2*: My wife, Bonnie M. Davis, MD is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license. *Part 3*: My wife, Bonnie M. Davis, MD is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license.

**de Wit, Harriet**: *Part 1*: I conducted a research study funded by Unilever in 2011.


**Dubocovich, Margarita**: *Part 1*: Takeda Pharmaceuticals North America Inc

**Duman, Ronald**: *Part 1*: Lilly, Forest, Bristol Myers Squibb, Taisho, Johnson & Johnson, Pfizer, Lundbeck, *Part 4*: Lilly, Forest, Lundbeck, Johnson & Johnson

**Duncan, Erica**: *Part 4*: Grant support from Brain Plasticity, Inc.
**Elliott, Mark:** Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Evins, A. Eden:** Part 1: Pfizer: Supplemental research support for the NIDA funded trial: R01 DA021245 Extended Duration Varenicline for Prevention of Smoking in Schizophrenia, Envivo Pharmaceuticals: Supplemental research support for the NIDA funded R01 DA030992 Proof of Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence, GSK: Supplemental research support for NIDA funded U01 DA019378 Cooperative Drug Discovery Group for Nicotine Dependence, Part 4: Pfizer: Supplemental research support for the NIDA funded trial: R01 DA021245 Extended Duration Varenicline for Prevention of Smoking in Schizophrenia, Envivo Pharmaceuticals: Supplemental research support for the NIDA funded R01 DA030992 Proof of Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence, GSK: Supplemental research support for NIDA funded U01 DA019378 Cooperative Drug Discovery Group for Nicotine Dependence

**Fan, Xiaoduo:** Part 1: Eli Lilly - advisory board, Part 4: Eli Lilly - investigator initiated clinical trial grant

**Fava, Maurizio:** Part 1: Advisory/Consulting: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvente, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; NuPathe;Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Bioblatory; Prexa Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; Teva; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.; Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource, Corp.; Wyeth-Ayerst Laboratories; Equity Holdings: Compellis; PsyBrain, Inc.; Royalty/patent, other income:
Patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to RCT Logic, LLC; and patent application for a combination of azapirones and bupropion in Major Depressive Disorder (MDD). Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolters Kluwer; World Scientific Publishing Co. Pte.Ltd.

Part 2: Belvoir Media Group for editing a newsletter: 2011-$12,000., Part 4: Abbott Laboratories; Alkermes, Inc.; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Clintara, LLC; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; NARSAD; NCCAM; NIDA; NIMH; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmavite® LLC; Photothera; Roche; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories


Foster, Marc: Part 1: Daktari Diagnostics, Inc., Visionscope Technologies, LLC, ImaCor, LLC, Part 5: Transparency Life Sciences, LLC


Gainetdinov, Raul: Part 4: I have research grants from F. Hoffmann La-Roche (Basel, Switzerland) on the topic of this presentation.

George, Tony: Part 1: Grant support from Pfizer, Speakers Bureau Pfizer, 2011 and 2012, Data Monitoring Committee, Novartis, 2011-present, Part 4: Pfizer - for studies of varenicline in smokers with mental illness, including schizophrenia.


Glatt, Stephen: Part 1: I serve as a scientific consultant to SynapDx Corp.

Gobbi, Gabriella: Part 1: Lilly, Astra-Zeneca, Lundbeck, Cosmas Therapeutics

Goff, Donald: Part 1: DSMB member: Otsuka Pharmaceuticals, Part 4: PamLab, Pfizer, Novartis, GSK

Gopal, Srihari: *Part 2:* Shareholder Johnson & Johnson (JNJ), Shareholder Merck (MRK), *Part 5:* Full time employee Johnson & Johnson (JNJ)

Gordon, Joshua: *Part 1:* Speaker at Pfizer Basic Research Division Neuroscience Symposium, honorarium, 2011,

Gründer, Gerhard: *Part 1:* Dr. Gründer has served as a consultant for Bristol-Myers Squibb (New York, NY), Cheplapharm (Greifswald, Germany), Eli Lilly (Indianapolis, Ind), Forest Laboratories (New York, NY, USA), Lundbeck (Copenhagen, Denmark), Otsuka (Rockville, Md.), Roche (Basel, Switzerland), and Servier (Paris, France). He has served on the speakers’ bureau of Bristol-Myers Squibb, Eli Lilly, Gedeon Richter (Budapest, Hungary), Otsuka, Roche, and Servier. He has received grant support from Alkermes, Eli Lilly, and Roche. He is co-founder of Pharma-Image – Molecular Imaging Technologies GmbH, Düsseldorf, *Part 2:* 2011: Eli Lilly, *Part 3:* 2011: Eli Lilly, *Part 4:* Dr. Gründer has received grant support from Alkermes, Eli Lilly, and Roche. He is co-founder of Pharma-Image – Molecular Imaging Technologies GmbH, Düsseldorf.


Graham, Danielle: *Part 5:* I am a full time employee of EMD Serono Research & Development Institute.


Greist, John: *Part 1:* I do not believe questions 2 and 4 are applicable because I do not know whether any/all of the companies with which I do business are "doing business with or proposing to do business with ACNP" and find that matter confusing., *Part 2:* eResearch Technology, Healthcare Technology Systems, Possibly Pfizer, though I expect something less than $10,000., If I own any stock in any pharmaceutical or device company it would be in retirement accounts such as the State of Wisconsin Retirement Plan over which I have no control. I have never purchased or held any pharmaceutical stocks in my personal investment account, nor has my spouse., *Part 3:* Please see #2 above., *Part 4:* AstraZeneca, eResearch Technology, Forest, Lilly, Novo Nordisk, Otsuka, Pfizer, Takeda, Transcept, UCB, *Part 5:* Healthcare Technology Systems is a medical assessment company. Though it is not technically a pharmaceutical/biotech/medical device company, I list it here to avoid any possible misunderstanding.

Gur, Raquel: *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

Gur, Ruben: *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.
Gurney, Mark: Part 1: Dr. Gurney is an employee of Tetra Discovery Partners., Part 2: Dr. Gurney is an employee of Tetra Discovery Partners., Part 3: Dr. Gurney is an employee of Tetra Discovery Partners., Part 5: Tetra Discovery Partners.

Haber, Suzanne: Part 1: Dr. Haber has received consultation fees from Medtronic, Inc and Pfizer, Inc.


Hasler, Gregor: Part 1: Servier (Suisse) SA, Lundbeck (Schweiz) AG, Schweizerische Gesellschaft für Bipolare Störungen, AstraZeneca, Eli Lilly (Suisse) SA, Part 4: Novartis Switzerland

Hen, Rene: Part 1: Serve on Scientific Advisory Boards for Roche Pharmaceuticals, Lundbeck and Servier

Heres , Stephan: Part 1: I have received honoraria from Janssen-Cilag, Eli Lilly, Sanofi-Aventis and Johnson & Johnson. , I have accepted travel or hospitality payment from Janssen-Cilag, Sanofi-Aventis, Johnson & Johnson, Pfizer, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis and Eli Lilly. , I have participated in clinical trials sponsored or supported by Eli Lilly, Janssen Cilag, Johnson & Johnson, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis, Servier, Pierre Fabre, Pfizer, Organon, Roche and Merck. , I have participated in advisory activities and boards for Janssen, Johnson & Johnson, Eli Lilly, Lundbeck and Roche.

Hermanson, Daniel: Part 1: DJH, LJM and SP have submitted a patent application entitled "Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation," which includes the compound LM-4131.


Higgs, Suzanne: Part 1: Academic Supervisor of PhD studentship part funded by P1vital, Part 4: Academic Supervisor of PhD studentship part funded by P1vital

Hollander, Eric: Part 1: research grants: Simons Foundation, Roche, Transcept, Forest, Coronado Biosciences, consultant: Roche, Coronado Biosciences, Part 4: research grants: Simons Foundation, Roche, Transcept, Forest, Coronado Biosciences,


Innis, Robert: Part 1: Eli Lilly has provide funds to NIMH to support my research., Part 4: Eli Lilly has provide funds to NIMH to support my research.
Iosifescu, Dan: Part 1: In the previous 36 months, Dr. Iosifescu has received research funding through Mount Sinai School of Medicine from AstraZeneca, Brainsway, Euthymics, Neosync, and Roche; he has received consulting fees from CNS Response, Otsuka, Servier and Sunovion., Part 4: In the previous 36 months, Dr. Iosifescu has received research funding through Mount Sinai School of Medicine from AstraZeneca, Brainsway, Euthymics, Neosync, and Roche; he has received consulting fees from CNS Response, Otsuka, Servier and Sunovion.

Jarskog, Lars: Part 1: Research grants from Sunovion, Amgen, Roche. DSMB board member - Janssen.

Javitt, Daniel: Part 1: Honoraria from Sunovion, BMS, Eli Lilly, Takeda, Omeros, Otsuka, Consensus Medical Communications, Guidepoint global, American Capital, Clearpoint communications, Vindico Medical Communication, and Clearview Healthcare. Research support from Pfizer and Roche; equity in, Glytech, Inc. and AASI; intellectual property rights for use of glycine, D-serine and glycine transport inhibitors in schizophrenia, and serves, on the advisory board of Promentis., Part 2: Columbia, NYS OMH, Glytech, Part 4: Pfizer, Roche

Kantrowitz, Joshua: Part 1: Dr. Kantrowitz reports having received consulting payments within the last 2 years from Otsuka Pharmaceuticals, Quadrant Health, RTI Health solutions, the Healthcare Advisory Board, Vindico Medical Education, Health Advances, LLC, Strategic Edge Communications. He owns a small number of shares of common stock in GlaxoSmithKline., Part 2: NYS OMH, Columbia, RFMH, St Luke's-Roosevelt, Part 4: He has conducted clinical research supported by the NIMH, the Stanley Foundation, Roche-Genetech, EnVivo, Psychogenics, Sunovion, Novartis, Pfizer, Lilly and GlaxoSmithKline.


Knight, Scott: Part 5: Sigma Aldrich

Kohler, Christian: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.


Lapidus, Kyle: Part 1: Dr. Lapidus has received support for this project from the Brain and Behavior Research Foundation’s Young Investigator Award and Apire Janssen Psychiatric Resident Research Scholars Award and serves as scientific advisor for Halo Neuro, Inc. He also participated in an interview on the future of antidepressants with LCN Consulting, Inc., Part 4: Dr. Lapidus has received support for this project from the Brain and Behavior Research Foundation’s Young Investigator Award and Apire Janssen Psychiatric Resident Research Scholars Award.


Malhotra, Anil: Part 1: Genomind
Mann, J. John: Part 2: Royalties from Research Foundation for Mental Health for C-SSRS, Part 4: Unrelated past grants from GSK and Novartis

March, Mary: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.


Marnett, Lawrence: Part 1: DJH, LJM and SP have submitted a patent application entitled "Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation," which includes the compound LM-4131.

Marx, Christine: Part 1: Applicant or co-applicant, pending patents on the use of neurosteroids and derivatives in CNS disorders and for lowering cholesterol (no patents issued, no licensing in place). Unpaid scientific advisor, Sage Therapeutics.

Mathalon, Daniel: Part 1: Consultant for Amgen, Consultant for BristolMyers Squibb


McCullumsmith, Cheryl: Part 1: Jansenn Pharmaceuticals : Suicide Advisory Board

McGorry, Patrick: Part 1: I have received honoraria for educational and consultancy activities and/or travel support to attend such consultancy meetings from Janssen Cilag, Servier and Roche and unrestricted research grant support from Janssen Cilag and Astra Zeneca, Part 4: Unrestricted research grant support from Janssen Cilag and Astra Zeneca


Murrough, James: Part 1: Dr. Murrough has received research support from Janssen Pharmaceuticals and Avanir Pharmaceuticals., Part 4: Dr. Murrough has received research support from Janssen Pharmaceuticals and Avanir Pharmaceuticals.

Nuechterlein, Keith: Part 1: Investigator-Initiated Research Grant from Janssen Scientific Affairs, LLC, Research grant from Brain Plasticity, Inc., Consultant and research grant, Genentech, Consultant, Otsuka, Part 4: Investigator-Initiated Research Grant from Janssen Scientific Affairs, LLC, Research grant from Brain Plasticity, Inc., Research grant from Genentech


O'Malley, Stephanie: Part 1: ACTIVE workgroup supported be Eli Lilly, Lundbeck, Alkermes, Pfizer, Johnson and Johnson, GSK, Abbott, Hazelden Foundation, Applied behavior research, Pfizer, Part 4: Eli Lilly contract, Pfizer medication supplies

Patel, Maxine: Part 1: Consultancy: Janssen; Endo; Amgen; Lundbeck, Principal or Chief Investigator for clinical studies: Amgen; Lundbeck, Part 4: Principal or Chief Investigator for clinical studies: Amgen; Lundbeck,

Patel, Sachin: Part 1: DJH, LJM and SP have submitted a patent application entitled "Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation," which includes the compound LM-4131.

Paul, Steven: Part 1: Alnylam Pharmaceuticals (Board of Directors), Constellation Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Karuna Pharmaceuticals (Board of Directors), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Tal Medical Pharmaceuticals (Scientific Advisory Board and Board of Directors), Third Rock Ventures (Venture Partner). , Part 2: Alnylam Pharmaceuticals (Board of Directors), Constellation Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Karuna Pharmaceuticals (Board of Directors), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Tal Medical Pharmaceuticals (Scientific Advisory Board and Board of Directors), Third Rock Ventures (Venture Partner). , Part 3: Alnylam Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Third Rock Ventures (Venture Partner). , Part 4: Alzheimer's Drug Discovery Foundation, AstraZeneca Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Alzheimer's Drug Discovery Foundation, NIH R01 grant.

Pearlson, Godfrey: Part 1: Consultant BMS 2012

Pelham, William: Part 1: Gave a talk at a conference in Japan that was sponsored by Janssen Pharmaceuticals

Perkins, Diana: Part 1: Consultant: Genentech/Roche, Sunovion, Otsuka
Peterchev, Angel: Part 1: Dr. Peterchev is inventor on patents and patent applications on TMS technology assigned to Columbia University and Duke University, including technology licensed to Rogue Research; was Principal Investigator on a research grant to Duke from Rogue Research and equipment donations to Columbia and Duke by Magstim, MagVenture, and ANS/St. Jude Medical; has received patent royalties from Rogue Research through Columbia for TMS technology; and has received travel support from Rogue Research through Duke., Part 3: Dr. Peterchev has received patent royalties from Rogue Research through Columbia University for TMS technology that he invented., Part 4: Dr. Peterchev was Principal Investigator on a research grant to Duke from Rogue Research and of equipment donations to Columbia and Duke by Magstim and MagVenture.

Phillips, Mary: Part 2: I have been a consultant for Cardiff University, Department of Psychological Medicine, UK. This relationship is due to end in 2013.

Pletcher, Mathew: Part 1: Employee of Pfizer, Part 5: Pfizer

Posner, Kelly: Part 1: Dr. Posner is the director of the Center for Suicide Risk Assessment. The Center, as part of an effort to help execute the FDA suicidality classification mandates, has received support from the following pharmaceutical companies: Abbott, Aerial Biopharma, Albany Molecular Research, Alder Biopharma, Alfresa, Alkermes, Amgen, Astellas Pharm, Astra Zeneca, Biogen, Biomarin Pharmaceutical, Biovail Technologies, Boehringer Ingelheim, Bracket, Bristol Myers Squibb, Cato Research, Celerion, Cephalon, Cetero Research, Chiesi Pharmaceuticals, Covance, CRI Worldwide, Daiichi Sankyo Company, Depomed, Douglas Pharmaceuticals/VersaPharm, Eisai, Elan, EnVivo, Epiomed, Forest, Gilead, GlaxoSmithKline, Grunenthal, GW Pharma Limited, Human Genome Sciences, i3 International, i3 Research, i3 Pharmaceutical Services, ICON Development Solutions, Impax Laboratories, INC Research, Ingenix, IntelGenx Corp, IntraCellular Therapies, Ironwood, IRIS, Isis, Ivax, Janssen, Jazz, Johnson & Johnson, Lilly USA, Lotus, Lundbeck, MedAvante, MedImmune, Merck, Mochida, Neurocrine Biosciences, Neuronex, Neurosearch, NextWave Pharma, Novartis, Noven, NovoNordisk, Omeros, Orexigen Therapeutics, Orion, Otsuka, Pamlab, Parexel, Pfizer, PGx Health, Pharmaceutical Research Associates, Pharmanet i3, Pierrel Research, PPD, Prana Biotechnology, ProPhase, Psyadon, QED Pharmaceuticals, Quintiles, Receptos, Reckitt Benckiser, Rho, Rhythm, Roche, Sanofi-Aventis, Schering-Plough, Schwarz Biosciences, SCOPE International, Sepracor, Shionogi, Shire, Siena Biotech, SK Life Science, Sunovion, Supernus Pharmaceuticals, Synosia Therapeutics, Takeda Global Research & Development Center, Takeda Pharmaceuticals, TauRx Therapeutics, Theravance, UCB Biosciences, UCB Korea, UCB Pharma, United BioSource Corp, Upsher-Smith Laboratories, Vaccinex, Valeant Pharmaceuticals, Vernalis, Vivus, WorldWide Clinical Trials, Wyeth Ayerst, Wyeth Pharmaceuticals, Wyeth Research, Xenopont and Zalicus. Dr. Posner receives royalty payments from the e-CSSRS, which are distributed to her by her employer, the Research Foundation for Mental Hygiene.


Healthcare, *Part 3*: None other than my primary employer: McLean Hospital/Partners Healthcare, *Part 4*: Cyberonics, Medtronic

**Ray, Lara**: *Part 1*: I am a paid consultant for GSK.

**Reynolds, Charles**: *Part 1*: none, *Part 2*: I receive an honorarium from the American Association for Geriatric Psychiatry, for service as associate editor of the American Journal of Geriatric Psychiatry, *Part 3*: none, *Part 4*: During the past three years I have received pharmaceutical supplies for my NIH sponsored clinical trials from Pfizer (venlafaxine, aripiprazole, donepezil) and Eli Lilly (duloxetine), *Part 5*: not applicable; primary employer = University of Pittsburgh and UPMC

**Risbrough, Victoria**: *Part 4*: Research grants awarded from Johnson and Johnson, Omeros Pharmaceuticals, Sunovion Pharmaceuticals, and Johnson and Johnson.


**Roffman, Joshua**: *Part 4*: Pamlab


**Ruparel, Kosha**: *Part 4*: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Russo, Scott**: *Part 4*: Dr Russo receives laboratory support from Johnson and Johnson to study IL-6 and depression.

**Sablinski, Tomasz**: *Part 5*: Auven Therapeutics, Transpartency Life Sciences


**Satterthwaite, Theodore**: *Part 4*: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Sawa, Akira**: *Part 4*: Research Support:, Astellas Pharm., Dainippon Sumitomo, Mitsubishi-Tanabe Pharm., Takeda, Johnson and Johnson, Consultant:, Pfizer, Asubio, Sucampo, Eli Lilly, Taisho,
Collaboration: Pfizer, Afraxis, Astellas Pharm., Dainippon Sumitomo, Mitsubishi-Tanabe Pharm., Takeda, Sanofis-Avenis, Johnson and Johnson

**Schadt, Eric:** *Part 1:* SAB for Pacific Biosciences and SAB for Berg, *Part 2:* SAB for Pacific Biosciences and SAB for Berg.

**Schork, Nicholas:** *Part 1:* Dr. Schork is a founder of CypherGenomics (http://www.cyphergenomics.com/) and on the board of MD Revolution (http://mdrevolution.com/) and has stock as a result.


**Simpson, Helen:** *Part 1:* Consultation for Quintiles, Inc. (on therapeutic needs for OCD), 9/2012, *Part 4:* Research support from Transcet Pharmaceuticals for ondansetron study 2011-2013, Research support for medication at no-cost from Janssen Pharmaceuticals 2006-2012 for NIMH funded study in OCD

**Smith, Mark:** *Part 5:* Former employee of AstraZeneca Pharmaceuticals in Wilmington DE, the company that funded/sponsored the study reported here., Current employee of Shire Pharmaceuticals in Wayne, PA.

**Stein, Murray:** *Part 1:* Care Management Technologies (Consultant), Up-to-Date (Co-Editor-in-Chief, Psychiatry), Depression and Anxiety [Wiley] (Associate Editor), *Part 2:* University of California San Diego, Va San Diego Healthcare System, Up-To-Date, *Part 3:* Up-To-Date, *Part 4:* Janssen (Co-Investigator on Research Contract)


Swanson, James: Part 1: I have been a consultant with Noven Pharmaceuticals and BLK Pharma, and I received indirect support from pharmaceutical companies from a professional organization, the European Network of Hyperkinetic Disorders (EUNETHYDIS), to make presentations at annual meetings.

Sweeney, John: Part 1: Consultant to Lilly, Takeda, Roche and BMS

Swift, Robert: Part 1: Consultant to Transcept Pharmaceuticals - received fee, Scientific Advisory Board for D&A Pharma - received honorarium and travel expenses to meeting, Consultant to Pharmaceutico CT - received fee and travel expense reimbursement, Part 2: Consultant to Pharmaceutico CT - fee and travel expense reimbursement

Tamminga, Carol: Part 1: Astellas; Eli Lilly; Intra-Cellular Therapies; Kaye Scholer LLP; Lundbeck; PureTech Ventures; NIMH; Am J Psychiatry; , Part 2: Am J Psychiatry; KayeScholer LLP; IntraCellular Therapies, Part 4: Sunovion

Thomas, Jason: Part 1: PhD studentship part funded by P1vital, Part 3: PhD studentship part funded by P1vital, Part 4: PhD studentship part funded by P1vital


Turetsky, Bruce: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

Uchida, Hiroyuki: Part 1: Dr. Uchida has received speaker’s honoraria from Otsuka Pharmaceutical, Janssen Pharmaceutical, Novartis Pharma, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, and Janssen Pharmaceutical within the past two years. , Part 4: Dr. Uchida has received grants from Pfizer, Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, GlaxoSmithKline, Shionogi, and Dainippon-Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharma, Janssen Pharmaceutical, and Yoshitomi Yakuhin within the past two years.

Uher, Rudolf: Part 1: Dr Uher co-chairs a steering board of a research project initiated and funded by Bristol Myers Squibb and collaborates with Pfizer, Glaxo-Smith Kline and Roche as part of the European
Union Innovative Medicine Initiative funded NEWMEDS project. Dr Uher has received no personal income from any pharmaceutical or biotech industry and holds no equity in companies active in medicine, pharmaceuticals or biotechnology.

**Van Zeeland, Ashley:** *Part 1:* Dr. Van Zeeland is a Co-founder and CEO of CypherGenomics (http://www.cyphergenomics.com/) and has stock as a result., *Part 5:* Cypher Genomics

**Vinogradov, Sophia:** *Part 1:* consultant to BrainPlasticity Institute

**Wahlestedt, Claes:** *Part 1:* Pfizer, OPKO

**Walker, Brendan:** *Part 4:* Completed a cooperative research agreement on 9/24/2011 with H. Lundbeck A/S, Copenhagen on the kappa-opoid mechanisms of nalmefene.

**Warden, Melissa:** *Part 1:* Stanford University has filed for patent protection on technology invented by Dr. Melissa R. Warden and Dr. Karl Deisseroth.


**Wigal, Tim:** *Part 1:* Otsuka and McNeil, *Part 4:* Eli Lilly, Noven, Shire and Rhodes Pharmaceuticals

**Wing, Victoria:** *Part 4:* Pfizer IIR Operating Grant 2012-2014 ($50,000), Pfizer IIR 2010-2013 (medication supply only), Pfizer GRAND Operating Grant 2013-2015 ($20,000)

**Winterer, Georg:** *Part 1:* Pharmalimage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), Boehringer Ingelheim (consulting), UCB Pharma (consulting, services), Pfizer (speaker bureau, grant), Focus Drug Development (consulting, services), Dritte Patent Portfolio Beteiligungsgesellschaft mbH & Co KG (consulting), Ratiopharm (consulting), *Part 2:* Pharmalimage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), UCB Pharma (consulting, services), Focus Drug Development (consulting, services), *Part 3:* Pharmalimage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), Focus Drug Development (consulting, services), *Part 4:* Pfizer/McNeill

**Wolf, Daniel:** *Part 4:* The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals.

**Wolf, Marina:** *Part 1:* I have 50,000 shares (~$50,000) in a non-publicly traded entity: Grace Laboratories LLC, 1755 Logans Knoll NE, Atlanta GA 30329. I do not receive any income at this time. There is no linkage to my research or to ACNP., *Part 2:* I have 50,000 shares (~$50,000) in a non-publicly traded entity: CIS Biotech Inc, 2701 North Decatur Rd, Decatur, GA 30033. I do not receive any income at this time. There is no linkage to my research or to ACNP., *Part 2:* I have 50,000 shares (~$50,000) in a non-publicly traded entity: Grace Laboratories LLC, 1755 Logans Knoll NE, Atlanta GA 30329. I do not receive any income at
this time. There is no linkage to my research or to ACNP., I have 50,000 shares (~$50,000) in a non-
publicly traded entity: CIS Biotech Inc, 2701 North Decatur Rd, Decatur, GA 30033. I do not receive any
income at this time. There is no linkage to my research or to ACNP.

**Wong, Dean:** *Part 1:* Consultant for Amgen and Concert Pharmaceuticals, *Part 2:* Johns Hopkins
University, School of Medicine, *Part 4:* Avid, Biotie, GE, Intracellular, J+J, Lilly, Lundbeck, Merck, NIH,
Otsuka, Roche, Sanofi-Aventis, Synosia

**Woods, Scott:** *Part 1:* Investigator-initiated grant from Pfizer, *Part 4:* Investigator-initiated grant from
Pfizer


**Youngstrom, Eric:** *Part 1:* Eric Youngstrom has consulted with Lundbeck and received past travel support
from Bristol-Myers Squibb. He has consulted with Penn State about analyses for a grant funded by
Pfizer, and received grant funding from NIMH.

**Zarate, Carlos:** *Part 1:* Dr. Zarate is listed as a co-inventor on a patent application for the use of
ketamine and its metabolites in major depression. Dr. Zarate has assigned his rights in the patent to the
U.S. government but will share a percentage of any royalties that may be received by the government.

**Zhang, H. Steve:** *Part 5:* Sangamo Biosciences

**Zorumski, Charles:** *Part 1:* I serve on the Scientific Advisory Board of Sage Therapeutics., *Part 2:* .

**Zukin, Stephen:** *Part 5:* Former employee of AstraZeneca Pharmaceuticals in Wilmington DE, the
company that funded/sponsored the study reported here., *Current employee of Forest Research
Institute in Jersey City, New Jersey.*

Following Faculty Had Nothing to Disclosure:

Dean Acheson
Jean Addington
Susanne Ahmari
Schahram Akbarian
Martin Alda
Ream Al-Hasani
Susan Amara
Mala Ananth
Katrin Arelin
Peter Bachman
Dewleen Baker
Tracy Bale
Ruben Baler
Elizabeth Balough
Michael Baumann
Jaime Becnel
Gillinder Bedi
Odeta Beggel
Aysenil Belger
Sabina Berretta
Wade Berrettini
Timothy Bestor
Bruno Biagianti
James Bibb
Elisabeth Binder
James Bjork
Jeffrey Borckardt
Jake Bosin
Jennifer Bossert
Kathleen Brady
Linda Brady
Jess Brallier
Timothy W. Bredy
Truman Brown
Michael Bruchas
Han Brunner
Katherine Burdick
Inga Burmann
Meryl Butters
Dan Buysse
Kristin Cadenhead
Catherine Cahill
Tyrone Cannon
Melanie Canterbury
Nicole Capik
Facundo Carillo
Marlene Carlson
Ricardo Carrion
Hannah Cates
Guillermo Cecchi
Moses Chao
Joseph Cheer
Alon Chen
Brandon Chuang
Toni-Kim Clarke
Paula Clayton
Brett Clementz
Christine Colvis
Wilson Compton
Mark Connelly
Robin Cooper
Joyonna Gamble-George
Sarah Garfinkel
Xiujuan Geng
Mark George
Susan George
Vincent Giguere
John Gilmore
Jay Gingrich
Santhosh Girirajan
Nitin Gogtay
Rita Goldstein
Raul Gonzalez
David Grandy
Kathleen Grant
Steven Grant
Rachel Greene
Nuria Gresa-Arribas
Amanda Guyer
Victoria Haghighi
Maureen Hahn
Tomas Hajek
Batsheva Halberstam
Katherine Ann Halmi
Ahmad Hameed
Robert Hamer
Bruce D. Hammock
Colleen Hanlon
Nolan Hartley
Karen Hartwell
Elizabeth Heller
J. Dee Higley
Noboru Hiroi
Georgia Hodes
Rachel Hodge
Daniel Hong
Hailan Hu
Thomas Hyde
Thomas Insel
Michael Irwin
Koko Ishizuka
Jacob Jacobsen
Andrew Jaffe
J. David Jentsch
Jarch Johanna
Jason Johannesen
Oralee Johnson
Sara Jones
Sheena Josselyn
Carla Shatz
Tomer Shechner
Pei-an Betty Shih
Sarah Short
David Shurtleff
Larry Siever
Mariano Sigman
Gail Silipo
Jogender Singh Tushir
Dorothy Sit
Phil Skolnick
Vikaas Sohal
Laili Soleimani
Nadia Solowij
Chandra Sripada
Beth Stevens
Camilla Stoltenberg
Scott Stroup
Garret Stuber
Regina Sullivan
Haosheng Sun
Lawrence Sung
Ezra Susser
James Swain
Jonathan Sweedler
Peter Szatmari
Philip Szieszko
Karen Szumlinski
Michael Taffe
Joseph Taylor
Panayotis Thanos
Paul Thompson
Wesley Thompson
Maarten Titulaer
Vi Tran
Gina Turrigiano
David Vaillancourt
Edwin van den Oord
Ashlee Van't Veer
Joris Veltman
Eric Vermetten
Arno Villringer
Susanna Visser
Aristotle Voineskos
Nora Volkow
Mark Von Zastrow
Terry Vrijenhoek
Elaine Walker
Ken Warren
Christopher Watkins
Daniel Weinberger
Anne West
Douglas Williamson
Katherine Wisner
Stephen Wisniewski
Catherine Wong
Marcelo Wood
Josh Woolley
Sandra Woolson
Yurong Xin
Jun Yang
Zhongfei Yang
Rachel Yehuda
Soojin Yi
Adelaide Yiu
Bangning Yu
Deborah Yurgelun-Todd
Kate Yurgil
Andrew Zalesky
Zane Zeier
Tai Zhou
Xianjin Zhou

Following Faculty Had No Disclosures:

Amy Arnsten
David Bredt
Z. Josh Huang
Linda Porrino
Carla Shatz
John Talpos
Gina Turrigiano